Remepy has raised $36M in a Series A financing round to expand its hybrid drug pipeline and fund global Phase 3 development of Hybridopa, its lead programme for Parkinson’s disease.

The financing, led by O.G. Venture Partners and M Ventures, the strategic venture arm of Merck KGaA, brings Remepy’s total capital raised to $62M.

The company said the funding will support pharmaceutical co-development partnerships, expansion of its hybrid drug pipeline and platform, and the global Phase 3 clinical development of Hybridopa, which is expected to begin in Q4 2026.

Investors in the round also included NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital and IT-Farm Corp.

Hybridopa moves towards Phase 3 development

Hybridopa is Remepy’s programme for Parkinson’s disease and combines a prescription medicine with a personalised, AI-driven therapeutic app.

The company reported Phase 2A results showing improvements in motor and non-motor symptoms in people with Parkinson’s disease. Remepy said the findings were supported by peer-reviewed publications examining the biological mechanisms behind the treatment’s effects.

Hybridopa remains investigational and has not been approved by the FDA.

Remepy said its hybrid drug approach combines pharmacological treatment with adaptive physical, cognitive and behavioural interventions delivered through software.

Michal Tsur and Or Shoval, co-CEOs of Remepy, said: “We believe medicine is entering a new era, where every breakthrough drug will be paired with personalized intelligence to maximize its impact for every patient.”

They added that the new funding would allow the company to advance Hybridopa into Phase 3 while expanding its approach across other therapeutic areas.

Pharmaceutical partnerships

Alongside the Parkinson’s programme, Remepy is developing partnerships with pharmaceutical companies around its hybrid drug platform.

The company recently announced a strategic collaboration with Merck KGaA to develop hybrid drugs across multiple indications, initially focusing on rare tumours.

The approach is based on combining conventional medicines with personalised digital interventions. Remepy said the model could allow pharmaceutical companies to develop additional intellectual property and support lifecycle management of existing and future medicines.

Dr Eyal Ben Ami, scientific lead at M Ventures, said: “Remepy’s pioneering Hybrid Drugs approach reflects the growing importance and applicability of integrating AI into the delivery of health and physical medicines.”

He added that the investment was intended to support development of the approach across multiple drug classes and disease areas.

The Series A comes as Remepy prepares Hybridopa for global Phase 3 development, with the company expecting the trial programme to begin in the fourth quarter of 2026.

The financing also gives the company additional resources to develop its wider pipeline and pursue further pharmaceutical partnerships around its hybrid drug platform.